Myelofibrosis: biology and treatment options. - Wikidata - awgldk - TriplyDB

Myelofibrosis: biology and treatment options.

Myelofibrosis: biology and treatment options.

http://www.wikidata.org/entity/Q36922494

about

Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

P2860

Q33753094-62FB8C13-3CC2-43AC-820F-4935357F77FF

P2860

Myelofibrosis: biology and treatment options.

http://www.wikidata.org/entity/Q36922494

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Myelofibrosis: biology and treatment options.

@en

type

label

Myelofibrosis: biology and treatment options.

@en

prefLabel

Myelofibrosis: biology and treatment options.

@en

P1433

Q36922494-C86128E9-1C24-4EAA-915D-9698875A28D2

P1476

Q36922494-93764E1B-9339-4011-8DBE-BCD30F94554A

P2093

Q36922494-1FC3E305-045A-4187-8D49-DF4102A7193E

P2860

Q36922494-108C04BC-DB00-4F0A-89D1-307CAB97BC36

Q36922494-14CD5396-3482-4583-BC9C-97CCDE8AB52F

Q36922494-1EB1E10F-2771-4387-834A-FEC6629ABDDE

Q36922494-32FF1B2B-2EE2-4527-AA0D-E48D75642B4D

Q36922494-380F7BF3-A8FF-44ED-94E6-717183E2178A

Q36922494-4735977D-D2A8-400B-8758-A6DF0CAC3AF8

Q36922494-4CAE05F9-9F9C-488C-A657-98CB93DD0158

Q36922494-4D294019-B40B-4248-9273-10852DA43EB2

Q36922494-4E4686ED-9240-4AEA-8894-7048BBC2F097

Q36922494-648D87D5-0B49-4314-8B9D-C7641022DA62

P304

Q36922494-488252CB-EC40-4D50-AA64-650D173E10ED

P31

Q36922494-EA9450E4-8E0E-44F4-BB12-F11E6D4AF44C

P356

Q36922494-F5C97C9B-6CF6-465B-A58F-2456AE210E9F

P433

Q36922494-16D39AD2-7DBC-4FA1-8FD8-D9E8EA0DF262

P577

Q36922494-A85B261D-9620-46FD-A923-CE61010F2155

P698

Q36922494-DD90C34C-C99E-4B36-9098-DC09BB1B1F4C

P356

J.1600-0609.2007.00937.X

P1433

European journal of haematology. Supplementum

P1476

Myelofibrosis: biology and treatment options.

@en

P2093

Francisco Cervantes

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

Advances in the therapy of chronic idiopathic myelofibrosis.

NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis.

Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.

P304

13-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0609.2007.00937.X

http://www.w3.org/2001/XMLSchema#string

P433

68

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17727559

http://www.w3.org/2001/XMLSchema#string